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Abstract Activation of protein kinase B (PKB) by growth 
factors has been demonstrated to proceed via phosphatidylino-
sitol 3-kinase (PI3-kinase). Here, we show that agents which 
raise intracellular cAMP can also stimulate PKB. However, this 
effect is not sensitive to wortmannin, indicating that it is PI3-
kinase independent. This activation does not appear to result 
from direct phosphorylation by protein kinase A (PKA) since 
GST-PKB is not an effective PKA substrate. In addition, the 
activation pathway of PKB by cAMP seems to be linked to that 
of growth factors, albeit downstream of PI3-kinase. Evidence for 
this is that a constitutive active PKB, T308D, S473D, containing 
activating mutations in the serine and threonine residues which 
are phosphorylated subsequent to PI3-kinase activation, cannot 
be further stimulated by cAMP elevations. Hence, these data 
suggest that, in addition to growth factors, cAMP can also lead 
to activation of PKB. This cAMP stimulatory action appears to 
require phosphorylation of T308 and S473, and hence would 
indicate that cAMP modulates the phosphorylation event of 
these PKB regulatory sites. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Protein kinase B (PKB), also referred to as akt or RAC 
kinase, is a serine/threonine protein kinase which was cloned 
by virtue of its homology to the A and C protein kinases, and 
is the cellular homolog of the product of the v-akt oncogene 
[1-3]. Structurally, the N-terminus contains a PH domain 
which is thought to be involved in the interaction of PKB 
with phospholipids [4-6], dimerization [7], and possibly inter-
action with other proteins [8]. The kinase domain is localized 
to the center of the protein. Regulatory sites for phosphoryl-
ation are found in the C-terminus [9]. The kinase is activated 
in response to treatment of cells with polypeptides acting 
through tyrosine kinase receptors such as PDGF, insulin, 
bFGF and EGF [4,10,11]. Stimulation of PKB in response 
to these agents is strictly dependent on the activity of PI3-
kinase for the following reasons: (i) it is inhibitable by wort-
mannin [4,10-12], (ii) PDGF receptor mutants which cannot 
interact with PI3-kinase fail to activate PKB [4,11], and (iii) 
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constitutively active forms of PI3-kinase are able to stimulate 
PKB [13,14]. Currently, a two-step model has been proposed 
to explain activation of PKB in response to growth factors 
[15,16]. Firstly, stimulation of PI3-kinase subsequent to en-
gagement of growth factor receptors leads to the production 
of PtdIns-3,4,5-P3, which can then be dephosphorylated by a 
specific phospholipid phosphatase to PtdIns-3,4-P2. The latter 
product has been shown to bind to the PH domain of PKB 
and is thought both to localize it to membranes and to di-
rectly activate the kinase. Next, PKB is phosphorylated on 
threonine 308 and serine 473 by unidentified kinase(s) [9]. 
Several lines of evidence implicate PKB in cell growth; the 
product of the v-akt oncogene is capable of transforming cells 
[17], overexpression of PKB in ovarian carcinomas has been 
demonstrated [18], and recently, data linking PKB with pro-
tection from apoptosis has been accumulating. PKB can me-
diate the anti-apoptotic effects of IGF-1 in neuronal cells [19], 
Rat-1 and COS-7 cells [20,21]. In addition, constitutively ac-
tive PKB results in the activation of p70S6k, another protein 
implicated in cellular growth processes [11]. However, at 
present the only physiological substrate known for PKB is 
glycogen synthase kinase 3 (GSK3) [22]. Because, to date, 
GSK3 has not been implicated in any processes regulating 
cell growth, this implies that other substrates are likely to exist 
for PKB which are important in controlling these pathways. 
Elevation in the intracellular cAMP level can have variable 
consequences on cellular proliferation depending on cell type 
and the nature of the activation [23]. In many cells, the effect 
of cAMP is to diminish cell growth and promote differentia-
tion, and in certain conditions cAMP is antagonistic to the 
effect of growth factors. In many cases the inhibition of cell 
growth by cAMP is thought to result from inhibition of MAP 
kinase cascade, which is crucial to cell proliferation [24-29]. 
However, this is clearly not the only mechanism through 
which cAMP is exerting its antiproliferative effects, since sev-
eral reports have demonstrated that it is possible to disasso-
ciate MAP kinase activity from cell proliferation after treat-
ment of cells with cAMP [30-32]. In addition to the MAP 
kinase cascade, cAMP has also been reported to negatively 
regulate the activity of p70S6k [33] and p27Klpl [34], proteins 
which are implicated in the progression of the cell cycle [35]. 
Increased levels of cAMP have also been implicated in the 
promotion of differentiation, including the conversion of 
3T3-L1 fibroblasts to adipocytes [36]. The overall picture 
from these studies is that in many cell types cAMP is inhib-
itory to cell growth. However, this does not hold true in all 
systems; in several cell types cAMP can mediate the action of 
growth promoting factors [37]. Moreover, the effects of cAMP 
on activation of p70S6k are not always inhibitory. In Swiss 
3T3 cells cAMP is mitogenic and can activate p70S6k [31]. 
Because cAMP and PKB are both implicated in processes 
controlling growth and differentiation, we were interested in 
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determining if c A M P exerted some of its effects through the 
modulat ion of P K B activation. To do this, we examined the 
effect of agents which can increase intracellular c A M P con-
centrations on the activity of PKB overexpressed in 293-
E B N A cells. We found that cAMP-elevating agents can in-
crease the activity of PKB through a mechanism which is 
independent of PI3-kinase. This activation does not appear 
to result from a direct phosphorylation of P K B by P K A , 
but it appears to converge on the same pathway which is 
utilized by growth factors. 
2. Materials and methods 
2.1. Materials 
Culture media and Geneticin were from Life Technologies, Inc. 
(Gaithersburg, MD). All chemicals not otherwise noted were from 
Sigma (St. Louis, MO). Insulin was a kind gift from Novo-Nordisk 
(Copenhagen, Denmark). [γ-32Ρ]ΑΤΡ was purchased from ICN 
(France). The QuickChange® Site Directed Mutagenesis Kit was 
from Stratagene (LaJolla, CA). All oligonucleotides were from Euro-
gentec (Seraing, Belgium). The T7Sequencing® Kit was from Pharma-
cia (Uppsala, Sweden) and Plasmid Maxi Plasmid Purification Kits 
were from Quiagen® (Chatsworth, CA). GST-PKB was a gift from 
Jean-Francois Tanti (INSERM U145). 
2.2. Culture and transfection of 293-EBNA cells 
293-EBNA cells are human embryo kidney cells that constitutively 
express the EBNA-1 protein from the Epstein Barr virus (Invitrogen, 
San Diego, CA). These cells were grown in Dulbecco's modified Ea-
gle's medium (DMEM) supplemented with 5% (v/v) fetal calf serum 
and 500 μg/ml geneticin. Exponentially growing cells were trypsinized, 
seeded at 1.25 x10 s cells/well in 6-well tissue culture dishes (3.5-mm 
diameter), and incubated for 3 days in 2 ml of growth medium. One 
microgram of supercoiled DNA (PKB constructs in pECE) was mixed 
with 100 μΐ of 0.25 M CaCl2 and 100 μΐ of 2 X BES (buffered saline 
containing 50 mM Ar,Ar-bis-2-hydroxyethyl-2-aminoethane sulfonic 
acid, pH 6.95, 280 mM NaCl, and 1.5 mM Na2HP04). The mixture 
was incubated for 30 min at room temperature before being added 
dropwise to the cells. After incubation for 15-18 h at 35°C under 3% 
C0 2 , the cells were then removed to an incubator at 37°C, 5% C0 2 
for 8 h before starvation in DMEM containing 0.2% (w/v) BSA for 
14 h. 
2.3. Immunoprecipitation and in vitro kinase assay 
293-EBNA cell extracts were prepared by lysing cells in a buffer 
containing 50 mM HEPES, pH 7.6, 150 mM NaCl, 10 mM EDTA, 
10 mM Na4P207 , 2 mM vanadate, 100 mM NaF, 0.5 mM PMSF, 
100 Ul/ml aprotinin, 20 μΜ leupeptin, 1% (v/v) Triton X-100 for 15 min 
at 4°C. The lysates were clarified by centrifugation at 15 000Xg for 
15 min at 4°C, and immunoprecipitated using an anti-HA (12CA5) 
antibody coupled to protein G-sepharose. After washing of the im-
munocomplexes, kinase activity was assayed using Crosstide [22] as 
a substrate in a reaction mixture containing 50 mM Tris, 10 mM 
MgCl2, 1 mM DTT, 5 μΜ ATP, 30μΜ Crosstide, and 3.3 \iC\ 
[γ-32Ρ]ΑΤΡ. The phosphorylation reaction was allowed to proceed 
for 30 min at 30°C, then stopped by spotting 40 μΐ onto Whatman 
P81 filter papers, and immersing in 1% (v/v) orthophosphoric acid. 
The papers were washed several times, rinsed in ethanol, air-dried, 
and the radioactivity was determined by Cerenkov-counting. Back-
ground values obtained from a mixture lacking cell lysate were sub-
tracted from all values. 
2.4. Construction of constitutive active PKB 
Constructs encoding HA-tagged PKB and ΔΡΗ-ΡΚΒ in the mam-
malian expression vector pECE were provided by Brian Hemmings, 
and have been described previously [12]. Mutations which changed 
both T308 and S473 to aspartate residues were made using the Quick-
Change Mutagenesis Kit. Mutations were confirmed by sequencing. 
2.5. Phosphorylation of GST-PKB by PKA 
GST-PKB was phosphorylated in vitro using 10 U of PKA cata-
lytic subunit in a reaction mix containing 40 mM HEPES, pH 7.2, 20 
mM MgCl2, 100 mM ATP, and 10 μ θ [γ-
32Ρ]ΑΤΡ. The reaction 
Fig. 1. Stimulating effect of agents raising intracellular cAMP on 
the activity of ΔΡΗ-ΡΚΒ in transfected 293-EBNA cells. Serum-
starved 293-EBNA cells overexpressing ΔΡΗ-ΡΚΒ were incubated 
for 15 min with the various agents at the following concentrations: 
insulin, 1 μΜ; forskolin, 10 μΜ; CPT-cAMP, 1 mM; PGEi, 
2.5 μΜ; and 8-Br-cAMP, 1 mM. At the end of the incubation peri-
od, cells were lysed, and ΔΡΗ-ΡΚΒ was immunoprecipitated and 
kinase activity was determined using Crosstide as a substrate as de-
scribed in Section 2. ΔΡΗ-ΡΚΒ activity is expressed as cpm of 32P 
incorporated into Crosstide, and fold-stimulation of basal level of 
nonstimulated cells is indicated above each column. Data are 
means ±SD of a representative of two separate experiments, each 
performed in triplicate. 
continued 10 min at room temperature before stopping in Laemmli 
buffer and subjecting to SDS-PAGE. Gels were stained, destained and 
autoradiography was performed. Radioactive bands were excised and 
quantified by Cerenkov counting. 
3. Results and discussion 
3.1. Compounds that increase intracellular cAMP activate 
PKB 
In an at tempt to look for a role of the cAMP-dependent 
signaling pathway in the activation of PKB, we tested, in 293-
E B N A cells transfected with Δ Ρ Η - Ρ Κ Β , the effect of com-
pounds which are known to elevate intracellular c A M P levels. 
As can be seen in Fig. 1, all of the c A M P elevating agents led 
to a significant increase in the activity of Δ Ρ Η - Ρ Κ Β . Forsko-
lin (1CT5 M) and C P T - c A M P (1 m M ) both increase the ac-
tivity of P K B by 2.8-fold. Prostaglandin Ei (2.5 X 1(Γ6 Μ) 
and 8-bromo-cAMP (1 m M ) were the least efficacious, leading 
to 2.0- and 1.9-fold increases in the activity with respect to 
nonstimulated cells. Although all the c A M P elevating com-
pounds led to significant increases in P K B activity, none 
were as efficient as insulin, which increased the kinase activity 
of Δ Ρ Η - Ρ Κ Β by a factor of 4.8. These different agents in-
crease c A M P by various mechanisms: forskolin directly acti-
vates adenylyl cyclase, PGEi binds to a G s coupled receptor 
which leads to activation of adenylyl cyclase, and 8-bromo-
c A M P and C P T - c A M P are cell permeable analogs of cAMP. 
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Fig. 2. Effect of pre-incubation with wortmannin on the kinase ac-
tivity of PKB. 293-EBNA cells transfected with PKB were serum-
starved prior to pre-incubation or not with 100 nM wortmannin. 
Subsequently, the cells were stimulated with either forskolin (10 μΜ, 
15 min), insulin (1 μΜ, 5 min), or a combination of both. The cells 
were then lysed, PKB was immunoprecipitated and kinase assays 
were performed as described, and results are expressed as cpm of 
32 P incorporated into Crosstide. Data are expressed as means ±SD 
of a representative of five comparable experiments, each performed 
in triplicate. 
Since the only common element to all these different drugs is 
the ability to elevate cAMP, we conclude that cAMP can 
activate ΔΡΗ-ΡΚΒ in transfected 293-EBNA cells. Similar 
results were obtained with the wild-type PKB construct using 
forskolin as an agonist (data not shown). 
3.2. cAMP activates PKB in a PI3-kinase-independent 
mechanism 
Stimulation of PKB in response to growth factor receptors 
has been shown to be dependent on PI3-kinase activation, 
since this stimulation is completely inhibited by wortmannin. 
To attempt to determine if the mechanism of activation of 
PKB by cAMP-elevating agents is similar to that of growth-
factor receptors, that is, dependent on PI3-kinase activity, we 
examined the effect of wortmannin on the cAMP-induced 
activation of PKB. As can be seen in Fig. 2, the activity of 
PKB induced by insulin in 293-EBNA cells transfected with a 
full-length construct of PKB is abolished by pretreatment of 
the cells with wortmannin. In contrast, the activity induced by 
forskolin was not significantly altered in the presence of wort-
mannin, indicating that the mechanism of activation of PKB 
by forskolin occurs by a PI3-kinase-independent mechanism. 
In addition, the PKB activity induced by the co-stimulation 
with insulin and forskolin was additive, and the component of 
the activity which was contributed by forskolin was not sen-
sitive to wortmannin. Comparable results were obtained with 
cells transfected with ΔΡΗ-ΡΚΒ (data not shown). These data 
demonstrate that PKB can be activated by two separate path-
ways : one which is dependent on activity of PI3-kinase, and 
one which is not. 
3.3. Activation of PKB by cAMP producing agents does not 
appear to result from a direct phosphorylation of PKB by 
PKA 
The most direct mechanism through which cAMP-elevating 
agents could lead to activation of PKB would be by a direct 
phosphorylation of PKB by PKA. Indeed, PKB contains a 
putative site for phosphorylation by PKA at serine-422. Since 
this site lies between the two phosphorylation sites, which 
have been shown to be involved in regulating the activity of 
PKB, phosphorylation of this site by PKA could lead to a 
conformational change in PKB, resulting in an increased ac-
tivity of PKB. 
To determine whether direct phosphorylation of PKB by 
PKA could account for the effect of cAMP elevating agents 
on PKB activity, we looked at phosphorylation of a GST-
PKB fusion protein by PKA catalytic subunit in vitro. Fig. 3 
shows the results from these experiments where differing 
quantities of GST-PKB were phosphorylated by PKA. These 
data show that apparently PKB can serve as a substrate for 
PKA in vitro. In order to be considered a physiological sub-
strate, the stoichiometry of phosphorylation must approach 
1 mole of phosphate transferred per mole of protein. How-
ever, we calculated that only 0.0036 moles of phosphate are 
transferred per mole of GST-PKB. In addition, we were un-
able to demonstrate that PKB immunoprecipitated from over-
expressing 293-EBNA cells can be phosphorylated by PKA 
(data not shown). Therefore, PKB is unlikely to serve as a 
direct physiological substrate for PKA. This implies that a 
protein(s) other than PKA are activated in response to eleva-
tion in intracellular cAMP which are involved in the PI3-ki-
nase-independent activation of PKB. 
3.4. Effect of cAMP producing agents on the activation of 
various PKB mutants 
Activation of PKB has been proposed to proceed by a two-
step mechanism. Initially, phospholipid products of PI3-ki-
nase are thought to bind to the PH domain of PKB serving 
Fig. 3. Phosphorylation of GST-PKB by PKA. Indicated quantities of GST-PKB were incubated with 10 U of PKA catalytic subunit as noted, 
for 10 min as described in Section 2. Bands were excised and quantified by Cerenkov counting and cpm are noted below the corresponding 
bands. 
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to localize the kinase to the membrane. Once in the mem-
brane, PKB is activated by phosphorylation at two residues 
in the C-terminus. To further ascertain the mechanism by 
which cAMP elevation leads to activation of PKB, we exam-
ined the effect of forskolin on the activation of different mu-
tants of PKB. As was shown in Figs. 1 and 2, activation of a 
PKB mutant which lacks the N-terminal 106 amino acids, the 
region comprising the PH domain, is identical to that of the 
full-length PKB. This indicates that the PH domain is not 
necessary for activation of PKB by forskolin, and therefore 
indicates that binding of phosphohpids to the PH domain of 
PKB is not essential for its activation. 
Secondly, we examined the activation by forskolin of a 
mutant of PKB which contains an aspartate residue at threo-
nine-308, and at serine-473. This mimics the effect of phos-
phorylation of these residues, and this mutant has been shown 
to be constitutively active [9]. If activation of PKB by cAMP 
converged on the same signaling pathway through which PKB 
is activated by insulin, except at a site which is downstream of 
PI3-kinase, it would be expected that stimulation of the cells 
with forskolin would have no effect on the activation of this 
mutant, which we have named PKB-CA However, in contrast, 
if cAMP activates PKB by a mechanism which is distinct from 
that of the phosphorylation of S473 and T308, then forskolin 
should be able to further activate the constitutively active 
PKB mutant. Fig. 4 shows the activation of PKB in cells 
overexpressing the constitutively active PKB. As can be 
seen, forskolin fails to lead to a further increase in the kinase 
activity of PKB-CA, indicating that the mechanism of activa-
tion of PKB by cAMP-elevating agents is similar to that 
which leads to phosphorylation at S473 and T308. This is 
also consistent with our data showing that PKB is not a direct 
substrate for PKA. 
Fig. 4. Effect of forskolin on the kinase activity of a constitutively 
active mutant of PKB. 293-EBNA cells transfected with PKB-CA 
were serum-starved prior to stimulation with either forskolin 
(10 μΜ, 15 min), insulin (1 μΜ, 5 min), or a combination of both. 
The cells were then lysed, PKB was immunoprecipitated and kinase 
assays were performed as described, and results are expressed as % 
activity as compared to nonstimulated cells. Data are expressed as 
means ± SEM of two independent experiments each performed in 
triplicate. 
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Fig. 5. Kinase activity of ΔΡΗ-ΡΚΒ with respect to time. 293-
EBNA cells transfected with ΔΡΗ-ΡΚΒ were serum-starved prior to 
stimulation with either forskolin (10 μΜ, 0) insulin (1 μΜ, ■), or 
the simultaneous addition of both (o)· The cells were then lysed, 
ΔΡΗ-ΡΚΒ was immunoprecipitated and kinase assays were per-
formed as described. Results are expressed as cpm of 32P incorpo-
rated into Crosstide. Data represent means ± SD of two independent 
experiments each performed in triplicate. 
3.5. Time course of activation ÁPH PKB by forskolin 
Recent data have demonstrated that, in some cell systems, 
the effects of cAMP-elevating agents can alter the time course 
but not the magnitude of the activation of MAP kinase by 
growth factors [30]. In an attempt to define the conditions 
which lead to a stimulation of PKB by cAMP elevation, we 
wished to examine the effect of forskolin on the activation of 
PKB over time. Shown in Fig. 5 is the activity of ΔΡΗ-ΡΚΒ 
as a function of time in response to insulin, forskolin, and 
insulin plus forskolin. As compared with reports in the liter-
ature of the time course of activation of the wild-type PKB 
which peaks 5 min after insulin stimulation, ΔΡΗ-ΡΚΒ activ-
ity seems to reach a maximum between 15 and 30 min. In 
addition, activation of ΔΡΗ-ΡΚΒ by cAMP elevating agents 
parallels that of the activation by insulin, and at all time 
points except 5 min, the activity induced by both insulin 
and cAMP elevating agents is close to additive. Therefore, 
the effect of cAMP on PKB activity does not vary as a func-
tion of time. 
Data in this report show that, in addition to the described 
activation of PKB which is dependent on PI3-kinase, PKB 
can also be activated by increases in intracellular cAMP con-
centrations in a manner which is independent of PI3-kinase. 
However, this activation does not appear to be due to a direct 
phosphorylation of PKB by PKA, and appears to ultimately 
be related to the same mechanism as the one used by PI 3-
kinase, that is, phosphorylation of T308 and S473. Support of 
this is given by the fact that the constitutively active PKB, 
which contains mutations mimicking phosphorylation of T308 
and S473 is unable to be further activated in response to 
cAMP. Previous reports have shown that PKB can be acti-
vated independently of PI3-kinase by cellular stress [8]. In 
contrast with the effect of cAMP elevation, this process re-
quired a functional PH domain, implying that the mechanisms 
are different or cell type specific. 
Further experiments are required to determine the mecha-
nism through which cAMP is activating PKB. We favor a 
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pathway which converges on that which is used by insulin at a 
point which is downstream of PI3-kinase. Since the activation 
of P K B by insulin in 293-EBNA is not maximal, if both 
c A M P and insulin resulted in activation of the same kinase(s) 
which phosphorylate T308 and S473, the effects would be 
additive. Of course, other potential mechanisms exist, for ex-
ample, c A M P could be inhibiting a phosphatase which is re-
sponsible for dephosphorylating, and thereby inactivating, 
PKB. It has long been known that c A M P can inactivate pro-
tein phosphatase 1, due to the phosphorylation and activation 
of inhibitor-1 by P K A [38]. In addition, okadaic acid, an 
inhibitor of phosphatases 1 and 2A [39], is also a strong acti-
vator of P K B [12]. However, if c A M P was stabilizing P K B in 
an active form due to the inhibition of a phosphatase, it 
would be expected that the stimulatory effects of c A M P would 
be greater at later time points. Since this is not the case, we do 
not favor this mechanism. 
In summary, we have shown that activation of P K B does 
not only proceed through PI3-kinase dependent signals, and 
multiple parallel, and/or convergent mechanisms appear to 
exist to lead to its activation. It will thus be of interest to 
determine physiologically the functional consequences of the 
interplay between these various different signal transduction 
pathways. 
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